Related references
Note: Only part of the references are listed.Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy
Sijin Guo et al.
NATURE COMMUNICATIONS (2020)
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration
Varun Goel et al.
NUCLEIC ACID THERAPEUTICS (2020)
Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+Breast Cancer
Long Zhang et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
RNA Nanoparticles as Rubber for Compelling Vessel Extravasation to Enhance Tumor Targeting and for Fast Renal Excretion to Reduce Toxicity
Chiran Ghimire et al.
ACS NANO (2020)
Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
Hanieh Hossein-Nejad-Ariani et al.
SCIENTIFIC REPORTS (2019)
Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein
Yu Zhang et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression
Fengmei Pi et al.
NATURE NANOTECHNOLOGY (2018)
RNA versatility, flexibility, and thermostability for practice in RNA nanotechnology and biomedical applications
Farzin Haque et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2018)
Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy
Peng Wang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Carrie J. Lovitt et al.
BMC CANCER (2018)
Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy
Congcong Xu et al.
CANCER LETTERS (2018)
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Charissa Kim et al.
CELL (2018)
Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy
Zhen Yang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Na Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Dendrimers for Drug Delivery
Abhay Singh Chauhan
MOLECULES (2018)
Progress and challenges towards targeted delivery of cancer therapeutics
Daniel Rosenblum et al.
NATURE COMMUNICATIONS (2018)
Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation
Miles A. Miller et al.
ACS NANO (2018)
Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy
Qingle Song et al.
NANO LETTERS (2017)
Size, Shape, and Sequence-Dependent Immunogenicity of RNA Nanoparticles
Sijin Guo et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years
Jianrong Zhang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Advancement of the Emerging Field of RNA Nanotechnology
Daniel Jasinski et al.
ACS NANO (2017)
Controllable Self-Assembly of RNA Tetrahedrons with Precise Shape and Size for Cancer Targeting
Hui Li et al.
ADVANCED MATERIALS (2016)
Effect of surface properties on liposomal siRNA delivery
Yuqiong Xia et al.
BIOMATERIALS (2016)
Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer
Deepak Chitkara et al.
THERAPEUTIC DELIVERY (2016)
Self-Assembled Core-Shell Nanoparticles for Combined Chemotherapy and Photodynamic Therapy of Resistant Head and Neck Cancers
Chunbai He et al.
ACS NANO (2015)
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Sachi Horibata et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Xi Chen et al.
NATURE (2014)
DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B
P. Zuazua-Villar et al.
CELL DEATH & DISEASE (2014)
Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
Mohamed Shehata Draz et al.
THERANOSTICS (2014)
Vascular Endothelial Cell Growth-Activated XBP1 Splicing in Endothelial Cells Is Crucial for Angiogenesis
Lingfang Zeng et al.
CIRCULATION (2013)
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells
Yi Shu et al.
NATURE PROTOCOLS (2013)
Fabrication of Stable and RNase-Resistant RNA Nanoparticles Active in Gearing the Nanomotors for Viral DNA Packaging
Jing Liu et al.
ACS NANO (2011)
Pharmacological Characterization of Chemically Synthesized Monomeric phi29 pRNA Nanoparticles for Systemic Delivery
Sherine Abdelmawla et al.
MOLECULAR THERAPY (2011)
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics
Dan Shu et al.
NATURE NANOTECHNOLOGY (2011)
Cell-Specific Aptamer-Mediated Targeted Drug Delivery
Jiehua Zhou et al.
OLIGONUCLEOTIDES (2011)
A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
Carla Lucia Esposito et al.
PLOS ONE (2011)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines
Bianca P. Gomez et al.
FASEB JOURNAL (2007)
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum et al.
NATURE BIOTECHNOLOGY (2007)
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells
Monique C. A. Duyndam et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Share Paper
